Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Proc Natl Acad Sci U S A
2014 Apr 08;11114:5195-200. doi: 10.1073/pnas.1322892111.
Show Gene links
Show Anatomy links
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain.
Richards MW
,
Law EW
,
Rennalls LP
,
Busacca S
,
O'Regan L
,
Fry AM
,
Fennell DA
,
Bayliss R
.
Abstract
Proteins of the echinoderm microtubule-associated protein (EMAP)-like (EML) family contribute to formation of the mitotic spindle and interphase microtubule network. They contain a unique hydrophobic EML protein (HELP) motif and a variable number of WD40 repeats. Recurrent gene rearrangements in nonsmall cell lung cancer fuse EML4 to anaplastic lymphoma kinase (ALK), causing expression of several fusion oncoprotein variants. We have determined a 2.6-Å crystal structure of the representative ∼70-kDa core of EML1, revealing an intimately associated pair of β-propellers, which we term a TAPE (tandem atypical propeller in EMLs) domain. One propeller is highly atypical, having a discontinuous subdomain unrelated to a WD40 motif in place of one of its blades. This unexpected feature shows how a propeller structure can be assembled from subdomains with distinct folds. The HELP motif is not an independent domain but forms part of the hydrophobic core that joins the two β-propellers. The TAPE domain binds α/β-tubulin via its conserved, concave surface, including part of the atypical blade. Mapping the characteristic breakpoints of each EML4-ALK variant onto our structure indicates that the EML4 TAPE domain is truncated in many variants in a manner likely to make the fusion protein structurally unstable. We found that the heat shock protein 90 (Hsp90) inhibitor ganetespib induced degradation of these variants whereas others lacking a partial TAPE domain were resistant in both overexpression models and patient-derived cell lines. The Hsp90-sensitive EML4-ALK variants are exceptions to the rule that oncogenic fusion proteins involve breakpoints in disordered regions of both partners.
Adams,
PHENIX: building new software for automated crystallographic structure determination.
2002, Pubmed
Adams,
PHENIX: building new software for automated crystallographic structure determination.
2002,
Pubmed
Chen,
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
2010,
Pubmed
Chen,
MolProbity: all-atom structure validation for macromolecular crystallography.
2010,
Pubmed
Choi,
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
2008,
Pubmed
Choi,
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
2010,
Pubmed
,
Echinobase
Collaborative Computational Project, Number 4,
The CCP4 suite: programs for protein crystallography.
1994,
Pubmed
De Keersmaecker,
Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
2005,
Pubmed
,
Echinobase
Eichenmuller,
The human EMAP-like protein-70 (ELP70) is a microtubule destabilizer that localizes to the mitotic apparatus.
2002,
Pubmed
,
Echinobase
Emsley,
Coot: model-building tools for molecular graphics.
2004,
Pubmed
Hamill,
Purification of a WD repeat protein, EMAP, that promotes microtubule dynamics through an inhibition of rescue.
1998,
Pubmed
,
Echinobase
Hegyi,
Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins.
2009,
Pubmed
Heuckmann,
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
2012,
Pubmed
Hueston,
The C. elegans EMAP-like protein, ELP-1 is required for touch sensation and associates with microtubules and adhesion complexes.
2008,
Pubmed
,
Echinobase
Katayama,
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
2011,
Pubmed
,
Echinobase
Lepley,
Sequence and expression patterns of a human EMAP-related protein-2 (HuEMAP-2).
1999,
Pubmed
,
Echinobase
Mohri,
Identification of functional residues on Caenorhabditis elegans actin-interacting protein 1 (UNC-78) for disassembly of actin depolymerizing factor/cofilin-bound actin filaments.
2004,
Pubmed
Neckers,
Hsp90 molecular chaperone inhibitors: are we there yet?
2012,
Pubmed
Normant,
The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
2011,
Pubmed
,
Echinobase
Pollmann,
Human EML4, a novel member of the EMAP family, is essential for microtubule formation.
2006,
Pubmed
Sang,
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
2013,
Pubmed
Sasaki,
The biology and treatment of EML4-ALK non-small cell lung cancer.
2010,
Pubmed
,
Echinobase
Sequist,
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
2010,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Suprenant,
EMAP, an echinoderm microtubule-associated protein found in microtubule-ribosome complexes.
1993,
Pubmed
,
Echinobase
Suprenant,
Conservation of the WD-repeat, microtubule-binding protein, EMAP, in sea urchins, humans, and the nematode C. elegans.
2000,
Pubmed
,
Echinobase
Takezawa,
Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
2011,
Pubmed
Tegha-Dunghu,
EML3 is a nuclear microtubule-binding protein required for the correct alignment of chromosomes in metaphase.
2008,
Pubmed
Thunnissen,
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.
2012,
Pubmed
Voegtli,
The structure of Aip1p, a WD repeat protein that regulates Cofilin-mediated actin depolymerization.
2003,
Pubmed
Ying,
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
2012,
Pubmed
Zhang,
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
2010,
Pubmed